Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Technologies Appoints James A. Johnson as Chief Financial Officer
NanoString Technologies Appoints James A. Johnson as Chief Financial Officer   Industry Veteran Brings More Than 20 Years of Life Sciences Financial Expertise SEATTLE, Wash. | October 3, 2012 – NanoString Technologies, Inc., a privately-held provider of life science tools for translational research
View HTML
Toggle Summary Aetna Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay
SEATTLE , May 09, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Aetna has added the Prosigna® Breast Cancer Gene Signature Assay to its Tumor Markers
View HTML
Toggle Summary American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Recommends Use of Prosigna (PAM50) for Guiding Treatment Decisions in Early Stage Breast Cancer Patients
Prosigna One of Only Two Assays to Receive Strong Recommendation Together With High Rating of Evidence Quality
View HTML
Toggle Summary Anthem Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay
SEATTLE , Sept. 05, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Anthem has issued a positive coverage decision for the Prosigna® Breast Cancer Gene Signature
View HTML
Toggle Summary Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment for NanoString's Prosigna® Breast Cancer Assay
SEATTLE , Jan. 10, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Blue Cross Blue Shield Association Evidence Street has issued a positive assessment of the
View HTML
Toggle Summary Cigna Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay
SEATTLE , May 26, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosigna® Breast
View HTML
Toggle Summary Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to be Presented at ASCO
Data Supporting Utility of the PAM50 Assay for Breast Cancer Gene Expression Profiling to be Presented at ASCO   NanoString Technologies Developing Distributed Assay Platform for Potential Use in Clinical Diagnostics SEATTLE, Wash., and CHICAGO, Ill | June 3, 2011   -  NanoString Technologies,
View HTML
Toggle Summary Digital Spatial Profiling Technology Enables Quantitative Protein Profiling in FFPE Tissue Providing Detailed Molecular Characterization of Immune Response to Tumors
The Yale School of Medicine Presents Validation of NanoString's Novel Digital Spatial Profiling Technology by Quantitative Immunofluorescence Technology at 2017 American Association for Cancer Research
View HTML
Toggle Summary ESMO Clinical Practice Guidelines for Breast Cancer Recommend the Use of Prosigna/PAM50 Assay for Determining Potential Benefit From Chemotherapy
SEATTLE , Sept. 9, 2015 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. , (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that the PAM50 gene signature, commercialized as the Prosigna ® Breast Cancer Gene Signature
View HTML
Toggle Summary Humana Issues Positive Coverage Decision for NanoString's Prosigna® Breast Cancer Assay
SEATTLE , Jan. 31, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Humana has issued a positive coverage decision for the Prosigna® Breast Cancer Gene Signature
View HTML